<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lomustine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lomustine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lomustine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11387" href="/d/html/11387.html" rel="external">see "Lomustine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12560" href="/d/html/12560.html" rel="external">see "Lomustine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709019"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lomustine causes myelosuppression, including fatal myelosuppression. Myelosuppression is delayed, dose-related, and cumulative, occurring 4 to 6 weeks after drug administration and persisting for 1 to 2 weeks. Thrombocytopenia is generally more severe than leukopenia. Cumulative myelosuppression from lomustine is manifested by greater severity and longer duration of cytopenias. Monitor blood counts for at least 6 weeks after each dose. Do not give lomustine more frequently than every 6 weeks.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Medication error prevention:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prescribe, dispense, and administer only enough capsules for one dose. Fatal toxicity occurs with overdosage of lomustine. Both health care provider and pharmacist should emphasize to the patient that only one dose of lomustine is taken every 6 weeks.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26999022"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gleostine</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867393"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>CeeNU</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F189639"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Alkylating Agent;</li>
<li>
                        Antineoplastic Agent, Alkylating Agent (Nitrosourea)</li></ul></div>
<div class="block doa drugH1Div" id="F189604"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dispense only enough capsules for a single dose; do not dispense more than one dose at a time (ISMP 2014). Repeat courses should only be administered after adequate recovery of leukocytes to &gt;4,000/mm<sup>3</sup> and platelets to &gt;100,000/mm<sup>3</sup>. Lomustine is associated with a moderate or high emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09dead53-637d-4488-92d0-d43c62dbd506">Brain tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain tumors: Note: </b>Doses should be rounded to the nearest 10 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Astrocytomas: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Glioblastoma, adjuvant therapy, MGMT-methylated tumors (off-label combination): Adults ≤70 years: <b>Oral: </b>100 mg/m<sup>2</sup> on day 1 every 6 weeks for 6 cycles (in combination with temozolomide and concurrent radiation therapy) (Herrlinger 2019). Refer to protocol for dosage modification details.</p>
<p style="text-indent:-2em;margin-left:6em;">Glioblastoma:</p>
<p style="text-indent:-2em;margin-left:8em;">PCV regimen (off-label combination): <b>Oral: </b>110 mg/m<sup>2</sup> on day 1 every 6 weeks for 7 cycles (following radiation therapy and in combination with procarbazine and vincristine) (Levin 2000).</p>
<p style="text-indent:-2em;margin-left:8em;">Single-agent therapy, recurrent glioblastoma: <b>Oral: </b>100 to 130 mg/m<sup>2</sup> once every 6 weeks until disease progression or unacceptable toxicity (Wick 2010) <b>or </b>110 mg/m<sup>2</sup> on day 1 every 6 weeks (maximum dose: 200 mg) for a maximum of 6 cycles (Taal 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Glioma, low grade, adjuvant therapy:</b> PCV regimen (off-label combination): <b>Note: </b>Patients with grade 2 astrocytoma, oligodendroglioma, or oligoastrocytoma were included in these trials. <b>Oral: </b>110 mg/m<sup>2</sup> on day 1 of each 8-week cycle for 6 cycles (following radiation therapy and in combination with procarbazine and vincristine) (Buckner 2016; Shaw 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Medulloblastomas: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Medulloblastoma, newly-diagnosed, average risk, adjuvant therapy (off-label combination): Adults ≤21 years: <b>Oral: </b>75 mg/m<sup>2</sup> once every 6 weeks for 8 cycles (following radiation therapy and in combination with cisplatin and vincristine) (Packer 2006; Packer 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oligodendrogliomas: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted: PCV regimen (off-label combination):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>130 mg/m<sup>2</sup> on day 1 every 6 weeks for up to 4 cycles prior to radiation therapy (in combination with procarbazine and vincristine) (Cairncross 2013; Cairncross 2006).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>110 mg/m<sup>2</sup> on day 1 every 6 weeks for 6 cycles (following radiation therapy and in combination with procarbazine and vincristine) (van den Bent 2006; van den Bent 2013).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991825"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer’s labeling. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:2em;">Kintzel 1995:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 46 to 60 mL/minute: Reduce dose to 75% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 31 to 45 mL/minute: Reduce dose to 70% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">Krens 2019:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 50 mL/minute: Reduce dose to 75% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Use is not recommended (Krens 2019). Due to its lipophilic nature, lomustine is not dialyzable (Canadian labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">CAPD: Reduce dose to 25% to 50% of normal dose (Aronoff 2007).</p></div>
<div class="block doha drugH1Div" id="F50989106"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer’s labeling. However, lomustine is hepatically metabolized and caution should be used in patients with hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have been recommended (Krens 2019):</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended.</p></div>
<div class="block doo drugH1Div" id="F20342068"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate chemotherapy dosing in adults with cancer with </i>
<i>a BMI ≥30 kg/m<sup>2</sup></i>
<i>: </i>Utilize patient's actual body weight (full weight) for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p></div>
<div class="block dot drugH1Div" id="F46133056"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematologic toxicity: Dosing adjustment for subsequent cycles:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dose adjustments should be based on nadir counts from prior dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Leukocytes ≥3,000/mm<sup>3</sup>, platelets ≥75,000/mm<sup>3</sup>: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">Leukocytes 2,000 to 2,999/mm<sup>3</sup>, platelets 25,000 to 74,999/mm<sup>3</sup>: Reduce dose to 70% of prior dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Leukocytes &lt;2,000/mm<sup>3</sup>, platelets &lt;25,000/mm<sup>3</sup>: Reduce dose to 50% of prior dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Nonhematologic toxicity:</b> Pulmonary fibrosis: Discontinue permanently.</p></div>
<div class="block doe drugH1Div" id="F189605"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F189621"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12560" href="/d/html/12560.html" rel="external">see "Lomustine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> At FDA approved dosages, lomustine should only be dispensed and administered as a single dose once every 6 weeks due to delayed myelotoxicity; serious errors have occurred when lomustine was inadvertently administered daily. Repeat courses should only be administered after adequate recovery of leukocytes to &gt;4,000/mm<sup>3</sup> and platelets to &gt;100,000/mm<sup>3</sup>. Details concerning dosage in combination regimens should also be consulted; dose, frequency, number of doses, and start date may vary by protocol and treatment phase.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Round doses to the nearest 10 mg. Lomustine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09dead53-637d-4488-92d0-d43c62dbd506">Brain tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain tumors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General dosing:</i> Manufacturer's labeling: Infants, Children, and Adolescents: Oral: Initial: 130 mg/m<sup>2</sup> as a single dose every 6 weeks (dosage reductions may be recommended for combination chemotherapy regimens).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Compromised marrow function:</i> Reduce initial dose to 100 mg/m<sup>2</sup> as a single dose once every 6 weeks; <b>Note:</b> Subsequent doses may require adjustment after initial treatment according to platelet and leukocyte counts.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Medulloblastoma:</i> Children ≥3 years and Adolescents: Limited data available: Oral: 75 mg/m<sup>2</sup> on day 0 of each chemotherapy cycle in combination with cisplatin, vincristine, and radiotherapy (Packer 2006; Packer 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gliomas:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Low grade: Infants, Children, and Adolescents: Oral: 110 mg/m<sup>2</sup> on day 3 of a 6-week cycle in combination with thioguanine, vincristine, and procarbazine for up to 8 cycles for low grade, nonoperable (usually) gliomas (including astrocytomas) (Ater 2012; Lancaster 2003).</p>
<p style="text-indent:-2em;margin-left:6em;">High grade: <i>Jakacki 2016</i>: Astrocytoma, glioblastoma: Children ≥3 years and Adolescents: Oral: 90 mg/m<sup>2</sup> on day 1 every 42 days (or repeated when counts recovered) in combination with temozolomide and following radiotherapy for a total of 6 cycles (Jakacki 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma: Note:</b> Although FDA approved (Gleostine prescribing information), other contemporary therapies have replaced the use of lomustine in the treatment of progressive Hodgkin lymphoma. Hodgkin lymphoma guidelines do not include lomustine as a treatment component for Hodgkin lymphoma management (ESMO [Eichenauer 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Initial: 130 mg/m<sup>2</sup> as a single dose every 6 weeks (dosage reductions may be recommended for combination chemotherapy regimens) (manufacturer's labeling): <b>Note:</b> Subsequent doses may require adjustment after initial treatment according to platelet and leukocyte counts.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Compromised marrow function:</i> Reduce initial dose to 100 mg/m<sup>2</sup> as a single dose once every 6 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment based on toxicity: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic toxicity (nadir for subsequent cycles):</p>
<p style="text-indent:-2em;margin-left:6em;">Leukocytes ≥3,000/mm<sup>3</sup>, platelets ≥75,000/mm<sup>3</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:6em;">Leukocytes 2,000 to 2,999/mm<sup>3</sup>, platelets 25,000 to 74,999/mm<sup>3</sup>: Administer 70% of prior dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Leukocytes &lt;2,000/mm<sup>3</sup>, platelets &lt;25,000/mm<sup>3</sup>: Administer 50% of prior dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Nonhematologic toxicity: Pulmonary fibrosis: Discontinue permanently.</p></div>
<div class="block dorp drugH1Div" id="F51128475"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51128476"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, lomustine is hepatically metabolized and caution should be used in patients with hepatic dysfunction.</p></div>
<div class="block adr drugH1Div" id="F189566"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression, leukopenia, second primary malignant neoplasm (including acute leukemia and myelodysplastic syndrome), thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity, increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, disorientation, dysarthria, lethargy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blindness, optic atrophy, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephron atrophy, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary infiltrates</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Respiratory: Pulmonary fibrosis (Dent 1982)</p></div>
<div class="block coi drugH1Div" id="F189580"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;">
<i>US labeling:</i> There are no contraindications listed in the manufacturer’s labeling.</p>
<p style="text-indent:0em;">
<i>Canadian labeling:</i> Hypersensitivity to lomustine or any component of the formulation; severe leukopenia and/or thrombocytopenia.</p></div>
<div class="block war drugH1Div" id="F189563"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Lomustine causes myelosuppression, which may result in fatal infections or bleeding. Hematologic toxicity is dose-related, delayed (occurring 4 to 6 weeks after drug administration and persisting for 1 to 2 weeks), and cumulative. Thrombocytopenia is generally more severe than leukopenia. Cumulative myelosuppression from lomustine is manifested by greater severity and longer duration of cytopenias. Do not administer lomustine more frequently than once every 6 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity (transaminase, alkaline phosphatase and bilirubin elevations) has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: May cause pulmonary toxicity (infiltrates and/or fibrosis). Pulmonary toxicity is usually related to cumulative doses &gt;1,100 mg/m<sup>2</sup>. May be delayed 6 months or longer after treatment initiation. Patients with baseline below 70% of predicted forced vital capacity or carbon monoxide diffusing capacity are at increased risk. Patients treated at a younger age may also be at increased risk for pulmonary toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Progressive renal failure with a decrease in kidney size has been reported. Use with caution in patients with renal impairment; may require dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: Long-term use of nitrosoureas is associated with the development of secondary malignancies, including acute leukemia and myelodysplasia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Medication error prevention: Lomustine should only be prescribed/dispensed as a single dose once every 6 weeks. Serious and fatal adverse events have occurred with overdosage (when lomustine was inadvertently administered daily). Health care providers should emphasize to the patient that only 1 dose of lomustine is taken every 6 weeks. The Institute for Safe Medication Practices (ISMP) recommends that prescribers only prescribe one dose at a time and pharmacies dispense only enough capsules for a single dose; in addition, patients should receive both verbal counseling and written instructions regarding proper dose and administration (ISMP 2014).</p></div>
<div class="block foc drugH1Div" id="F189575"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gleostine: 10 mg, 40 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F189559"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F189582"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Gleostine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $134.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $539.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1,490.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867394"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CeeNU: 10 mg, 40 mg</p></div>
<div class="block adm drugH1Div" id="F803164"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Lomustine is associated with a moderate or high emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administering on an empty stomach may reduce the incidence of nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Varying strengths of capsules may be required to obtain necessary dose. Dispense only enough capsules for a single dose; do not dispense more than one dose at a time (ISMP 2014). Do not break capsules. If contact with skin occurs, immediately wash area (thoroughly). Avoid exposure to broken capsules.</p></div>
<div class="block admp drugH1Div" id="F52613173"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Lomustine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administering on an empty stomach may reduce the incidence of nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">Varying strengths of capsules may be required to obtain necessary dose. Dispense only enough capsules for a single dose; do not dispense more than one dose at a time (ISMP 2014). Do not break capsules. If contact with skin occurs, immediately wash area thoroughly; avoid exposure to broken capsules.</p></div>
<div class="block hazard drugH1Div" id="F49104550"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F189576"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Brain tumors:</b> Treatment of primary and metastatic brain tumors (after appropriate surgical and/or radiotherapeutic procedures).</p></div>
<div class="block mst drugH1Div" id="F2136824"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lomustine may be confused with bendamustine, carmustine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lomustine should only be administered as a single dose once every 6 weeks; serious and fatal adverse events have occurred when lomustine was inadvertently administered daily. The manufacturer and the Institute for Safe Medication Practices (ISMP) recommend prescribing, dispensing, and administering only enough capsules for a single dose (ISMP 2014).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F189633"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F189568"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307995"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who may become pregnant should use effective contraception during treatment and for 2 weeks after the final lomustine dose. Patients with partners who may become pregnant should use effective contraception during treatment and for 3.5 months after the final lomustine dose.</p></div>
<div class="block pri drugH1Div" id="F189583"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to lomustine may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F4044513"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lomustine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the nursing infant, the manufacturer does not recommend breastfeeding during treatment and for 2 weeks after the final lomustine dose.</p></div>
<div class="block mop drugH1Div" id="F189573"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelet count (weekly for at least 6 weeks after a dose), hepatic and renal function tests (periodic). Monitor pulmonary function tests (baseline and periodic). Monitor for secondary malignancies. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F189562"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lomustine inhibits DNA, RNA, and protein synthesis via alkylation and carbamylation of DNA and RNA; lomustine is cell cycle non-specific (Perry 2012).</p></div>
<div class="block phk drugH1Div" id="F189579"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Crosses blood-brain barrier; CNS concentrations are high (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to active metabolites (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Metabolites: 16 to 48 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: ~3 hours (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~50%, as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F189585"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ccnu schoeller | Lomustin (Ccnu)</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cecenu</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ccnu</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Citostal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ceenu | Prava</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Belustine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cecenu</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ccnu | Cecenu | Ceenu</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lomustine medac</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Belustine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lomustine medac | Lucostine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Belustine | Cecenu</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cecenu</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Lomtin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ccnu | Ceenu</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Belustine | Cecenu | Lomoother</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Belustine | Cecenu | Ceenu | Lomustine medac</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cecenu | Lomustine eureco pharma | Lomustine medcor</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ceenu | Gleostine | Lomustine medac</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ceenu combo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Belustine | Cecenu | Ceenu | Lomustin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ceenu | Gleostine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cecenu | Ceenu</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cecenu | Ceenu</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ceenu | Lomustine medac</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lomustine medac</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ccnu | Ceenu | Lomustine medac</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ccnu | Ceenu</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Belustine | Lomustine medac</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ccnu</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cecenu | Ceenu</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ceenu | Lomustin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ceenu</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22665535">
<a name="22665535"></a>Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2012;30(21):2641-2647.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/22665535/pubmed" id="22665535" target="_blank">22665535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27050206">
<a name="27050206"></a>Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. <i>N Engl J Med</i>. 2016;374(14):1344-1355. doi:10.1056/NEJMoa1500925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/27050206/pubmed" id="27050206" target="_blank">27050206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782910">
<a name="16782910"></a>Cairncross G, Berkey B, Shaw E, et al; Intergroup Radiation Therapy Oncology Group Trial 9402. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. <i>J Clin Oncol</i>. 2006;24(18):2707-2714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/16782910/pubmed" id="16782910" target="_blank">16782910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23071247">
<a name="23071247"></a>Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. <i>J Clin Oncol</i>. 2013;31(3):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/23071247/pubmed" id="23071247" target="_blank">23071247</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  CeeNU (lomustine) [product monograph]. Montreal, Canada: Bristol-Myers Quibb Canada: February 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7179192">
<a name="7179192"></a>Dent RG. Fatal pulmonary toxic effects of lomustine. <i>Thorax</i>. 1982;37(8):627-629. doi:10.1136/thx.37.8.627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/7179192/pubmed" id="7179192" target="_blank">7179192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32169225">
<a name="32169225"></a>Eichenauer DA, Aleman BMP, André M, et al; ESMO Guidelines Committee. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2018;29(suppl 4):iv19-iv29. doi:10.1093/annonc/mdy080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/32169225/pubmed" id="32169225" target="_blank">32169225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19124807">
<a name="19124807"></a>Federico M, Luminari S, Iannitto E, et al. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>J Clin Oncol</i>. 2009;27(5):805-811.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/19124807/pubmed" id="19124807" target="_blank">19124807</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gleostine (lomustine) [prescribing information]. Miami, FL: NextSource Biotechnology, LLC; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi: 10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30782343">
<a name="30782343"></a>Herrlinger U, Tzaridis T, Mack F, et al; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2019;393(10172):678-688. doi:10.1016/S0140-6736(18)31791-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/30782343/pubmed" id="30782343" target="_blank">30782343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Institute for Safe Medication Practices (ISMP). Acute Care Medication Safety Alert. 2014;19(14):1-4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27006176">
<a name="27006176"></a>Jakacki RI, Cohen KJ, Buxton A, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. <i>Neuro Oncol</i>. 2016;18(10):1442-1450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/27006176/pubmed" id="27006176" target="_blank">27006176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12892235">
<a name="12892235"></a>Lancaster DL, Hoddes JA, Michalski A. Tolerance of nitrosurea-based multiagen chemotherapy regime for low-grade pediatric gliomas. <i>J Neurooncol</i>. 2003;63(3):289-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/12892235/pubmed" id="12892235" target="_blank">12892235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11051233">
<a name="11051233"></a>Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. <i>Clin Cancer Res</i>. 2000;6(10):3878-3884.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/11051233/pubmed" id="11051233" target="_blank">11051233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11208845">
<a name="11208845"></a>Medical Research Council Brain Tumor Working Party. Randomized Trial of Procarbazine, Lomustine, and Vincristine in the Adjuvant Treatment of High-Grade Astrocytoma: A Medical Research Council Trial. <i>J Clin Oncol</i>. 2001;19(2):509-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/11208845/pubmed" id="11208845" target="_blank">11208845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16943538">
<a name="16943538"></a>Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. <i>J Clin Oncol</i>. 2006;24(25):4202-4208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/16943538/pubmed" id="16943538" target="_blank">16943538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10561268">
<a name="10561268"></a>Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. <i>J Clin Oncol</i>. 1999;17(7):2127-2136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/10561268/pubmed" id="10561268" target="_blank">10561268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23099653">
<a name="23099653"></a>Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group Trial A9961. <i>Neuro-Oncology</i>. 2013,15:97-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/23099653/pubmed" id="23099653" target="_blank">23099653</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Perry MC. Chemotherapeutic agents: Lomustine. <i>The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851558">
<a name="22851558"></a>Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. <i>J Clin Oncol.</i> 2012;30(25):3065-3070. doi:10.1200/JCO.2011.35.8598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/22851558/pubmed" id="22851558" target="_blank">22851558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.1">
<a name="Smetzer.1"></a>Smetzer J, Cohen M, eds. With oral chemotherapy, we simply must do better! <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2014;19(14):1-4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25035291">
<a name="25035291"></a>Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncol</i>. 2014;15(9):943-953. doi:10.1016/S1470-2045(14)70314-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/25035291/pubmed" id="25035291" target="_blank">25035291</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23071237">
<a name="23071237"></a>van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. <i>J Clin Oncol</i>. 2013;31(3):344-350. doi:10.1200/JCO.2012.43.2229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/23071237/pubmed" id="23071237" target="_blank">23071237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782911">
<a name="16782911"></a>van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. <i>J Clin Oncol</i>. 2006;24(18):2715-2722. doi:10.1200/JCO.2005.04.6078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/16782911/pubmed" id="16782911" target="_blank">16782911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124186">
<a name="20124186"></a>Wick W, Puduvalli VK, Chamberlain MC. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. <i>J Clin Oncol</i>. 2010;28(7):1168-1174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lomustine-drug-information/abstract-text/20124186/pubmed" id="20124186" target="_blank">20124186</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9569 Version 271.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
